期刊文献+

依碳氯替泼诺的结构分析研究 被引量:2

Spectra and Structure Data Analysis and Identification of Loteprednol Etabonate
下载PDF
导出
摘要 对依碳氯替泼诺的红外光谱(IR)、紫外光谱(UV)、质谱(MS)、氢氢相关谱(1H1HCOSY)、碳谱(DEPT45、DEPT90、DEPT135)、碳氢相关谱(HMQC)数据和解析进行了全面的报道。对所有的1HNMR、13CNMR谱的信号进行了归属,讨论了质谱的主要碎片离子的可能裂解方式和红外所对应的官能团的振动吸收形式、紫外特征吸收峰所对应的不饱和共轭体系电子跃迁能量。 The infrared spectrum, ultraviolet spectrum, mass spectrum, H-1 nuclear magnetic resonance spectrum, C-13 nuclear magnetic resonance spectra ( 1313, DEPT- 45, 90, 135), H-1-H-1 correlated spectroscopy (H-1-H-13 COSY), (H-1 detected) heteronuclear multiple-quantum coherence (HMQC) of loteprednol etabonate were reported and interpreted. All the H-1 NMR and C-13 NMR chemical shifts were assigned by means of H-1-H-1 COSY and HMQC. The chemical structure of the main characteristic fragmentations, pi --> pi * electron transition, and the vibrations of functional groups of the compound were discussed. The molecular structure of loteprednol etabonate has been identified.
出处 《分析化学》 SCIE EI CAS CSCD 北大核心 2005年第3期351-354,共4页 Chinese Journal of Analytical Chemistry
基金 国家自然科学基金资助项目(No.20075004)
关键词 氯替泼诺 特征吸收峰 不饱和 质谱 MS IR NMR 电子跃迁能 共轭体系 碎片 loteprednol etabonate infrared spectrum ultraviolet spetrum mass spectrum nuclear magnetic resonance spectra
  • 相关文献

参考文献11

  • 1Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J. Drugs of Today, 2000, 36 (5): 313~320.
  • 2Bodor N. Pharmazie, 2001, 56: s67~s74.
  • 3Bodor N S. B E Patent, 889563, 1981.
  • 4Sherif Z, Pleyer U. Ophthalmologica, 2002, 216 (5): 305~315.
  • 5Druzgala P, Hochhaus G, Bodor N. J. Steriod Biochem. Mol. Biol., 1991, 38: 149~154.
  • 6Bordor N, Murakami T, Wu W M, Winwood D, Howes J F. Pharm. Res., 1995, 12: 869~874.
  • 7Druzgala P, Wu W M, Winwood D, Howes J F, Reaves T A. Invest Ophthalmaol. Visual Sci., 1991, 32(4): 735.
  • 8Howes J F, Baru H, Vered M, Noumann R. J. Ocular Pharmacol., 1994, 10: 289~293.
  • 9Bodor N, Wu W M, Murakami T, Engel S. Pharm. Res., 1995, 12(6): 875~879.
  • 10Rachwal S, Druzgala P, Liu Z Z, Vlasak J, Brewster M E, Pop E. Steroids, 1998, 63 (4): 193~201.

同被引文献17

  • 1KLAAS W, MICHIEL C, KAREN R, et al. Rapidquantification of pharmaceuticals and pesticides in passivesamplers using ultra high performance liquid chromatographycoupled to high resolution mass spectrometry [J]. JChromatogrA, 2011,1218(51): 9162-9173.
  • 2ZHAO Y S,MIAO D Z,WANG L K, et al. Preparationtechnics of mezlocillin sodium: China, 1634929 [P].2005-07-06.
  • 3Ch.P(2005)VOlII(中国药典 2005 年版.二部)[S]. 2005:Appendix 22-24, 38-39.
  • 4Ch.P(2010)VolII(中国药典 2010 年版.二部)[S]. 2010:608-609.
  • 5Atlas of Infrared Spectra of Drugs Vol I (药品红外光谱集.第一卷)[S]. 1995: Spectrum number 627.
  • 6SUN Y Q, HU Y Z. Analytical Chemistry(分析化学)[M].Beijing: Science Press, 2006: 333.
  • 7李钢,徐群为,李瑞,程永科,黄长高.那格列奈的多晶型与溶解度[J].化学学报,2007,65(24):2817-2820. 被引量:14
  • 8Sadeek S A, E1-Shwiniy W H. Metal complexes of the fourth generation quinolone antimicrobial drug gatifloxacin: Synthesis, structure and biological evaluation[J]. Journal of Molecular Structure,2010,977(1-3):243-253.
  • 9Gurwitz M D, Jerry H. Serious adverse drug effects: Seeing the trees through the forest[J]. The New England Journal of Medicine, 2006,354 (13) : 1413-1415.
  • 10Masood I, Bhargava R, Abroad Z, et at. Gatifloxacin-indueed purpura; An unusual adverse drug reaction[J]. Journal Indian Academy Of Clinical Medicine, 2005,6 (3) : 239-240.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部